Ensign Peak Advisors
SABS icon

Ensign Peak Advisors’s SAB Biotherapeutics SABS Stock Holding History

Ensign Peak Advisors’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.57M Sell
1,172,641
-202,969
-15% -$755K 0.01% 583
2026
Q1 		$5.27M Buy
+1,375,610
New +$5.49M 0.01% 522

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ensign Peak Advisors's SABS Position: Q2 2026 in Review

Ensign Peak Advisors reduced its SAB Biotherapeutics (SABS) stake by 15% in Q2 2026, selling an estimated $755K and leaving 1,172,641 shares worth $4.57M. The position accounts for 0.01% of the portfolio, ranked #583.

Ensign Peak Advisors first reported a position in SABS in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.27M in Q1 2026. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Ensign Peak Advisors held 1,172,641 shares of SAB Biotherapeutics worth $4.57M as of Q2 2026.
  • Ensign Peak Advisors sold 202,969 SAB Biotherapeutics shares in Q2 2026, an estimated $755K.
  • SAB Biotherapeutics made up 0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #583 holding.
  • Ensign Peak Advisors first reported a position in SAB Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • Ensign Peak Advisors's SAB Biotherapeutics position peaked at $5.27M in Q1 2026.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.